Improved outcome with high-dose rituximab (HD-R) with G/GM-CSF and autologous stem cell transplantation (ASCT) for relapsed aggressive B-cell non-Hodgkin's lymphomas (NHL): The impact of histologies of follicular (FL) origin.

被引：0
|
作者：
Khouri, IF [1 ]
Saliba, RM [1 ]
Acholonu, S [1 ]
Okoroji, GJ [1 ]
Hosing, C [1 ]
Fayad, L [1 ]
Couriel, DR [1 ]
Pro, B [1 ]
Giralt, S [1 ]
Andersson, B [1 ]
Younes, A [1 ]
McLaughlin, P [1 ]
Champlin, RE [1 ]
机构：
[1] Univ Texas, MD Anderson Canc Ctr, Houston, TX 77030 USA
来源：
BLOOD | 2003年 / 102卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
2716
引用
收藏
页码：735A / 736A
页数：2
相关论文
共 50 条
  • [21] Comparison of the sequential high-dose chemotherapy followed by autologous stem cell support with and without rituximab in relapsed and refractory aggressive non-Hodgkin's lymphoma.
    Sieniawski, M
    Staak, JO
    Scheuss, H
    Glossmann, JP
    Diehl, V
    Engert, A
    Josting, A
    BLOOD, 2004, 104 (11) : 263A - 263A
  • [22] Augmented high-dose regimen of cyclophosphamide, carmustine, and etoposide with autologous hematopoietic stem cell transplantation for relapsed and refractory aggressive non-Hodgkin's lymphoma
    Robertson, MJ
    Abonour, R
    Hromas, R
    Nelson, RP
    Fineberg, NS
    Cornetta, K
    LEUKEMIA & LYMPHOMA, 2005, 46 (10) : 1477 - 1487
  • [23] Yttrium-90 ibritumomab tiuxetan combined with high-dose beam chemotherapy and autologous stem cell transplantation for relapsed/refractory B-cell non-Hodgkin's lymphoma
    Shimabukuro-Vornhagen, A.
    Josting, A.
    Scheid, C.
    Huebel, K.
    Boldt, F.
    Dietlein, M.
    Engert, A.
    Schnell, R.
    ANNALS OF ONCOLOGY, 2008, 19 : 241 - 242
  • [24] Yttrium-90 ibritumomab tiuxetan combined with high-dose BEAM chemotherapy and autologous stem cell transplantation for relapsed/refractory B-cell non-Hodgkin's lymphoma
    Shimabukuro-Vornhagen, A.
    Josting, A.
    Huebel, K.
    Scheid, C.
    Dietlein, M.
    Engert, A.
    Schnell, R.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [25] Feasibility and Efficacy of High-Dose Melphalan, Cyclophosphamide, Etoposide, and Dexamethasone (LEED) Chemotherapy with or without Rituximab Followed by Autologous Stem Cell Transplantation for Aggressive and Relapsed Non-Hodgkin’s Lymphoma
    Li-na Han
    Jin Zhou
    Takayuki Hirose
    Yosuke Imai
    Takuro Ishiguro
    Takaaki Chou
    International Journal of Hematology, 2006, 84 : 174 - 181
  • [26] Feasibility and efficacy of high-dose melphalan, cyclophosphamide, etoposide, and dexamethasone (LEED) chemotherapy with or without rituximab followed by autologous stem cell transplantation for aggressive and relapsed non-Hodgkin's lymphoma
    Han, Li-na
    Zhou, Jin
    Hirose, Takayuki
    Imai, Yosuke
    Ishiguro, Takuro
    Chou, Takaaki
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2006, 84 (02) : 174 - 181
  • [27] HEALTH ECONOMIC OUTCOME ANALYSIS OF STEM CELL MOBILIZATION WITH GRANULOCYTE COLONY-STIMULATING FACTOR (G-CSF) PLUS PLERIXAFOR VERSUS G-CSF ALONE IN PREPARATION FOR AUTOLOGOUS STEM CELL TRANSPLANTATION (ASCT) IN PATIENTS WITH NON-HODGKIN'S LYMPHOMAS (NHL)
    Pusic, I
    Kymes, S. M.
    Lambert, D. L.
    Gregory, M.
    DiPersio, J. F.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2010, 16 (02) : S212 - S212
  • [28] Efficiency of in vivo purging with Rituximba following by high-dose therapy (HDT) with autologous peripheral blood stem cell transplantation (PBSCT) in B-cell non-Hodgkin's lymphomas (NHL).: A single institution study.
    Haioun, C
    Delfau-Larue, MH
    Beaujean, F
    Beaumont, JL
    Belhadj, K
    Pautas, C
    Kirova, Y
    Allain, A
    Gaulard, P
    Farcet, JP
    Reyes, F
    BLOOD, 2000, 96 (11) : 184A - 184A
  • [29] Novel Combination Of Lenalidomide-Rituximab Provides An Effective Bridge To Stem Cell Transplantation In Relapsed and/Or Refractory Aggressive B-Cell Non-Hodgkin's Lymphomas: A Single Center Experience
    Cai, Qingqing
    Chen, Yiming
    Zou, Dehui
    Badillo, Maria
    Zhou, Shouhao
    Zhang, Liang
    Lopez, Elyse R.
    Jiang, Wenqi
    Huang, Hui-qiang
    Lin, Tongyu
    Wang, Michael
    BLOOD, 2013, 122 (21)
  • [30] Autologous hematopoietic stem cell transplantation (ASCT) following high-dose therapy (HDT) for non-Hodgkin's lymphoma (NHL) in adults 60 years of age and older.
    Gopal, A
    Gooley, T
    Golden, J
    Maloney, D
    Bensinger, W
    Petersdorf, S
    Appelbaum, F
    Press, O
    BLOOD, 1999, 94 (10) : 170A - 170A
12345